
IMUNON Unveils Exciting Phase 1-2 OVATION 2 Study Results: IMNN-001’s Progress Against Advanced Ovarian Cancer
Delving Deeper into the World of IMNN-001: Unraveling the Dose-Dependent Mechanism In the ever-evolving landscape of pharmaceutical research, a recent study has shed new light on the dose-dependent effects of IMNN-001, a promising therapeutic agent. This intriguing finding reveals that the 100mg/m2 dose is associated with a 20% increase in IL-12 levels compared to the…